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Methotrexate (MTX)-associated myelopathy is a rare but serious complication of 
MTX-based chemotherapy.  
Case report: A 54-year-old woman with leptomeningeal metastasis from breast 
cancer was admitted to our hospital with progressive paraparesis. Three months 
earlier, ventriculoperitoneal shunting for malresorptive hydrocephalus had been 
performed, followed by whole brain radiation with 10 x 3 Gy. Because of recurrent 
leptomeningeal metastasis, 4 cycles of intrathecal chemotherapy with 15 mg MTX 
and 4 mg dexamethasone every 5 days were administered without folinate rescue. 
Five days after the last cycle, she developed bloody diarrhea, emesis and 
pancytopenia. Filgrastim, platelet transfusions and antibiotics were initiated. While 
the patient recovered from hematological and gastrointestinal toxicity, progressive 
neurological deficits emerged, and the patient was transferred to the neurooncology 
service. Upon admission, 16 days after the last intrathecal injection, a high-grade 
spastic paraparesis (MRC grade 1-2) with urinary retention and anal incontinence 
was present. Sensory deficits were absent. No malignant cells were found in the 
CSF. Protein was 2828 mg/l (normal: 0-550 mg/l), lactate was 4.2 mmol/l (normal: 
1.2-2.1 mmol/l). The concentration of MTX in the CSF was below the limit of 
detection. Cultures from blood and CSF remained sterile. Magnetic resonance (MR) 
imaging of the spinal cord demonstrated hyperintense intramedullary lesions 
throughout the cervical and thoracic segments suggestive of subacute MTX-induced 
myelopathy (fig. 1), without contrast enhancement.  
Although plasma levels of folate, vitamin B12 and homocysteine were normal, we 
substituted high doses of the key metabolites of the methyl-transfer pathway: S-
adenosylmethionine (SAM), 200 mg three times daily i.v., folinate 80 mg once daily 
i.v., cyanocobalamine, 100 µg once daily i.v. and methionine, 5 g once daily per os. 
Three days later, marked improvement with resolution of paraparesis from MRC 
grade 1-2 to MRC grade 3 was noted. After one week, all therapy was continued 
orally. There was some further improvement, and the patient was referred to a 
rehabilitative program. Upon reevaluation one month later, there was residual 
paraparesis (MRC 3-4) and persisting urinary incontinence. MR imaging showed 
resolution of the intramedullary lesions (fig. 1). Genetic analyses revealed 
homozygosity for the A allele of methylenetetrahydrofolate reductase (MTHFR) 
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c.1298A>C (p.E429A), whereas other genetic variants of folate/ methionine 
metabolism associated with MTX neurotoxicity were not present (details not shown; 
Linnebank et al., 2009). 
Discussion: 
Acute and chronic encephalopathies are the most common types of MTX-induced 
neurotoxicity. In contrast, subacute myelopathy is rare [Vezmar,2003] (2). While it is 
notable that folinate rescue was not administered in our patient, this is often viewed 
as dispensable for low-dose MTX regimens including intrathecal therapy. The severe 
MTX-induced toxicity in our patient - both systemic and in the CNS - is therefore 
indicative of hypersensitivity towards MTX. Systemic and intrathecal therapy with 
MTX interferes with folate/ methionine metabolism, increasing both plasma and CSF 
concentrations of homocysteine and decreasing SAM, methionine and 5-
methyltetrahydrofolate concentrations [Quinn, 2004] (3). MTX neurotoxicity is 
associated with polymorphic mutations of folate/ methionine metabolism that may 
influence nucleic acid and SAM synthesis as well as homocysteine metabolism. 
MTHFR is necessary to synthesize a cofactor for methionine synthesis, 5-
methyltetrahydrofolate, from 5,10-methylenetetrahydrofolate. Homozygosity for the 
wildtype A-allele of the MTHFR variant c.1298A>C, as observed here, has been 
reported in association with a higher risk of MTX-neurotoxicity. However, the effect of 
this variant on SAM synthesis has not yet been investigated, and homozygosity for 
the A-allele is common in the normal Caucasian population Linnebank, 2009] (5). 
Thus, the relevance of this genotype for the neurotoxicity of the patient reported here 
remains speculative. Nevertheless, substitution with SAM, 5-methyltetrahydrofolate 
or methionine normalizes CSF levels of folate/ methionine metabolites and promotes 
remyelination in children affected by inborn errors of folate/ methionine metabolism 
[Surtees, 1991] (6). We therefore considered substitution of high doses of different 
folate metabolites acting at multiple levels of the methionine synthesis pathway a 
promising strategy in to achieve the best functional MTX rescue in the affected neural 
tissue. To our knowledge, this is the first report of substitution of multiple metabolites 
of folate/ methionine metabolism for acute/subacute MTX-induced neurotoxicity. The 
patient´s rapid improvement following initiation of therapy may indicate a benefit 
derived from this regimen given the relentless progression of symptoms before, 
although spontaneous recovery from MTX-induced myelopathy can not fully be 
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excluded as alternative explanation. In summary, substitution with SAM itself 
accompanied by components necessary for endogenous SAM synthesis, like 
methionine, folate/ribofoline and vitamin B12, may be a safe and promising strategy 
for the treatment of MTX-induced neurotoxicity. Considering folinate rescue for 
intrathecal MTX therapy may help to avoid systemic toxicity. 
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Figure legends  
Figure 1 
MRI of the cervical and thoracic spinal cord at presentation (A) and after four weeks 
of substitution with multiple folate metabolites (B). T2-weighted sagittal and 
transversal images at the level of the cervical spinal cord without administration of 
gadolinium. 
 
